Figure 3. Lenvatinib effect in AAA patient-derived SMCs.

(A) Live-cell imaging (for up to 3 days) detected a reduced VSMC migration (wound scratch assay) upon lenvatinib stimulation (0.1 μM) versus control (vehicle: DMSO, 0.1%). Lenvatinib significantly decreased VSMC proliferation but did not change survival and cell apoptosis (indicated by Caspase3/7-positive cells). (B) Gene expression changes following lenvatinib treatment (data are presented as mean of biological triplicates + SEM, *P < 0.05; ****P < 0.0001; 1-tailed t test).